THE UNEXPECTED MEDIASTINAL EXTENSION IN A CASE OF LUNG CANCER: THE ROLE OF IMAGING AND MULTIPLE SIDE-EFFECTS WITH CLINICAL RELEVANCE FOLLOWING TOPIRAMATE THERAPY
DOI:
https://doi.org/10.29121/granthaalayah.v6.i9.2018.1270Keywords:
Unexpected, Mediastinal, Relevance, ClinicalAbstract [English]
Bronchopulmonary neoplasm is the first cause of cancer mortality in the world and a major public health problem, affecting 17% of men and 12% of women; in this context it is very important and necessary to establish the correct diagnosis in the early stages of the disease in order to initiate the required surgical therapy [1]
Downloads
References
Tammemägi M.C. (2015) Application of risk prediction models to lung cancer screening: a review. J Thorac Imaging, Mar;30(2), 88-100. https://doi.org/10.1097/RTI.0000000000000142. DOI: https://doi.org/10.1097/RTI.0000000000000142
Cipu C. Daniela (2015) Value of radio-imagistic explorations in the assessment of mediastinal lung cancer extension, with the emphasis on the computed tomography examination, in the lesion balance and the quantification of staging. PhD Thesis, elaborated at “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania.
Selva A., Bolibar I., Torrego A., Pallarès M.C. (2014) Impact of a program for rapid diagnosis and treatment of lung cancer on hospital care delay and tumor stage. Tumori, Nov-Dec; 100(6), e 243-9. https://doi.org/10.1700/1778.19286.
Biton V., Montouris G.D., Ritter F. (1999) A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group, Neurology, 52, 1330-1337. DOI: https://doi.org/10.1212/WNL.52.7.1330
Faught E. (2007) Topiramate in the treatment of partial and generalized epilepsy. Neuropsychiatr Dis Treat, Dec; 3(6), 811-821.
Arroyo S, Dodson W.E., Privitera M.D. (2005) Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand, 112, 214-222. DOI: https://doi.org/10.1111/j.1600-0404.2005.00485.x
Meador K.J., Loring D.W., Vahle V.J. (2005) Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology. 64, 2108-2014. DOI: https://doi.org/10.1212/01.WNL.0000165994.46777.BE
Bendaly E.A., Jordan C.A., Staehler S.S., Rushing D.A. (2007) Topiramate in the treatment of neuropathic pain in patients with cancer. Support Cancer Ther, Sep 1;4(4), 241-246. https://doi.org/10.3816/SCT.2007.n.021. DOI: https://doi.org/10.3816/SCT.2007.n.021
Gruden J.F., Webb W.R., Naidich D.P., McGuiness G. (1999) Multinodular disease: anatomic localization at thin-section CT-multireader evaluation of a simple algorithm. Radiology, Mar 210(3), 711-720. https://doi.org/10.1148/radiology.210.3r99m21711.
Sheth S., Hamper U., Stanley D.B., Wheeler J.H., Smith P.A.(1999) US guidance for thoracic biopsy: a valuable alternative to CT. Radiology, Mar 210(3), 721-726. DOI: https://doi.org/10.1148/radiology.210.3.r99mr23721
Wiffen P.J., Derry S., Lunn M.P., Moore R.A. (2013) Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. Aug 30;(8), CD008314. doi: 10.1002/14651858.CD008314.pub3. DOI: https://doi.org/10.1002/14651858.CD008314.pub3
Shank R.P., Gardocki J.F., Streeter A.J. (2000) An overview of the pre-clinical aspects of topiramate: pharmacokinetics, and mechanism of action. Epilepsia, 41Suppl 1, 53-59.
Rosenfeld W.E., Doose D.R., Walker S.A. (1999) A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol, 20, 339-344. DOI: https://doi.org/10.1016/S0887-8994(99)00011-9
Gisclon L.G., Riffits J.M., Sica D.A. (1993) The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharmaceutical Research, 10, S397.
Reife R.A., Pledger G.W. (1997) Topiramate as adjunctive therapy in refractory partial epilepsy; pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia, 38, 531-533. DOI: https://doi.org/10.1111/j.1528-1157.1997.tb04515.x
Loescher W., Schmidt D. (2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia, 47, 1253-1284. DOI: https://doi.org/10.1111/j.1528-1167.2006.00607.x
Glauser T.A. (1997) Topiramate. Semin Pediatr Neurol, 4, 34-42. DOI: https://doi.org/10.1016/S1071-9091(97)80007-1
Biton V., Edwards K.R., Montouris G.D. (2001) Topiramate titration and tolerability. Ann Pharmacother, 35, 73-179. DOI: https://doi.org/10.1345/aph.10093
Bialer M., Doose D.R., Murthy B., Curtin C., Wang S.S., Twyman R.E., Schwabe S. (2004) Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 43(12), 763-780.doi:10.2165/00003088-200443120-00001. DOI: https://doi.org/10.2165/00003088-200443120-00001
Caldwell, G.W., Wu, W.N., Masucci, J.A. (2005) European Journal of Drug Metabolism and Pharmacokinetics, 30, 151-164. doi:10.1007/BF03190614 DOI: https://doi.org/10.1007/BF03190614
Faught E., Wilder B.J., Ramasy R.E. (1996) Topiramate-controlled dose-ranging trial in refractory partial epilepsy using 20-, 400-, and 600-mg daily dosages. Topiramate YD Study Group, Neurology, 46, 1684-1690.
Shorvon S. (1996) Safety of topiramate: Adverse events and relationships to dosing. Epilepsia, 37(Suppl 2), S18-S22. doi: 10.1111/j.1528-1157. 1996.tb06029.x
Merino-Salas S., Arrabal-Polo M.A., Cano-Garcia Mdel C., Arrabal-Martin M. (2014) Calcium nephrolithiasis induced by topiramate. Arh Esp Urol, Apr;67(3), 284-287.
Dumitraşcu V., Matusz Anca Alexandra, Cinca Rodica, Grecu Daniela Ştefania (2004) Drug-induced calculi. Identification, structure and composition. Archives of the Balkan Medical Union, 40, 31-37.
Wilner A., Raymond K., Polland R. (1999) Topiramate and metabolic acidosis, Epilepsia, 40, 792-795. DOI: https://doi.org/10.1111/j.1528-1157.1999.tb00781.x
Kuo R.I., Moran D.E., Kim D.H. (2002) Topiramate-induced nephrolithiasis. J Endourol, 16, 229-231. DOI: https://doi.org/10.1089/089277902753752188
Matusz Anca Alexandra (1995) The value of some complex investigations in the study of kidney stones and microlithiasis in children. PhD Thesis, elaborated at “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania.
Thambi L., Kapcala L.P., Chambers W. (2002) Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Ophtalmol, 120(8), 1108. doi:10.1001/archopht.120.8.1108 DOI: https://doi.org/10.1001/archopht.120.8.1108
Stella F., Caetano D., Cendes F., Guerreiro C.A.M. (2002) Acute psychotic disorders induced by topiramate. Report of two cases. Arquivos de Neuro-Psiquiatria, 60(2), 1678-1680. http://dx.doi.org/10.1590/S0004-282X2002000200019 DOI: https://doi.org/10.1590/S0004-282X2002000200019
Downloads
Published
How to Cite
Issue
Section
License
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
